CTOs on the Move

Heron Therapeutics

www.appharma.com

 
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.appharma.com
  • 123 Saginaw Dr
    Redwood City, CA USA 94063
  • Phone: 650.366.2626

Executives

Name Title Contact Details

Similar Companies

Talley Group

Talley Group | Specialists in pressure relieving mattresses and cushions, electric bed frames, negative pressure wound therapy, IPC, and infection control

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.

I.C.H. Corporation

I.C.H. Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Servier

Servier Laboratories is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France.